Stockreport

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio Limited - Class A Ordinary shares  (ZURA) 
PDF Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseasesExpe [Read more]